News
Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies
- This patent protects the use of glenzocimab in thrombotic diseases until 2036
- This patent has already been granted in the United States and Singapore and is in the process of being granted in other countries such as Japan
Press Release:
CardiacVascularNews:
- This patent protects the use of glenzocimab in thrombotic diseases until 2036
- This patent has already been granted in the United States and Singapore and is in the process of being granted in other countries such as Japan
Press Release:
CardiacVascularNews: